𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Assessment of complex movements reflects dysfunction in Huntington’s disease

✍ Scribed by Carsten Saft; Jürgen Andrich; Nina-Marie Meisel; Horst Przuntek; Thomas Müller

Publisher
Springer
Year
2003
Tongue
English
Weight
219 KB
Volume
250
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Assessment of simple movements reflects
Assessment of simple movements reflects impairment in Huntington's disease
✍ Carsten Saft; Jürgen Andrich; Nina-Marie Meisel; Horst Przuntek; Thomas Müller 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

Clinical rating, caudate atrophy, disturbed movement performance, neuropsychological testing, and age-related genetic disease load (CAG index) are tools that reflect impairment after onset of Huntington's disease (HD). Objectives were to compare scored HD symptoms, results of neuropsychological test

Assessment of involuntary choreatic move
Assessment of involuntary choreatic movements in Huntington's disease—Toward objective and quantitative measures
✍ Ralf Reilmann; Stefan Bohlen; Florian Kirsten; E. Bernd Ringelstein; Herwig W. L 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 460 KB

## Abstract Objective measures of motor impairment may improve the sensitivity and reliability of motor end points in clinical trials. In Huntington's disease, involuntary choreatic movements are one of the hallmarks of motor dysfunction. Chorea is commonly assessed by subitems of the Unified‐Hunti

Assessment of adaptive functioning in hu
Assessment of adaptive functioning in huntington's disease
✍ Dr. Frederick W. Bylsma; Johannes Rothlind; Michelle R. Hall; Susan E. Folstein; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 682 KB

## Abstract The Huntington's Disease Activities of Daily Living (HD–ADL) scale is a 17‐item informant‐completed instrument for rating adaptive functioning in Huntington's disease (HD) patients. To assess the reliability and clinical correlates of the HD–ADL, it was administered along with the Mini‐

The Montreal Cognitive Assessment as a s
The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease
✍ Aleksandar Videnovic; Bryan Bernard; Wenqing Fan; Jeana Jaglin; Sue Leurgans; Ka 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 524 KB

## Abstract Cognitive dysfunction is one of the hallmarks of Huntington's disease (HD) and may precede the onset of motor symptoms. The Montreal Cognitive Assessment (MoCA), a brief cognitive screening instrument with high specificity and sensitivity for detecting early cognitive impairments, has n

Assessment of coenzyme q10 tolerability
Assessment of coenzyme q10 tolerability in huntington's disease
✍ Dr. A. Feigin; K. Kieburtz; P. Como; C. Hickey; D. Abwender; C. Zimmerman; K. St 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 273 KB

## Abstract We performed a 6‐month open‐label trial to evaluate the tolerability and efficacy of coenzyme Q10 (CoQ) in 10 patients with Huntington's disease (HD), Subjects were evaluated at baseline, 3 months, and 6 months using the HD Rating Scale (HDRS), the HD Functional Capacity Scale (HDFCS),